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Renal denervation
Home blood pressureBackground: Catheter-based percutaneous renal denervation therapy (RDN) is a controversially discussed
treatment-strategy for patients with resistant arterial hypertension. Home blood pressure monitoring (HBPM)
is superior to ofﬁce blood pressure (OBP) measurements documenting effects of drug or interventional therapy
and for predicting cardiovascular morbidity and mortality. We therefore aimed at comparing effects of RDN on
OBP and HBPM.
Methods: 28 patients with resistant hypertensionwere studied; 21 patients (29–85 years,median 67 years, 5.4±
1.3 antihypertensive drugs) were included into the treatment arm and 7 patients (37–70 years, median 68 years,
5.1 ± 2.2 antihypertensive drugs) served as controls. RDN was performed with a Medtronic™ radiofrequency
catheter-ablation-system. For OBP and HBPM measurements patients were followed up to 6 months. For
controls, a mean of approximately 378 measurements in 167 ± 13.5 days was included into analysis. In RDN
patients follow-up was 157.7 ± 61.8 days with a mean of approximately 323 ambulatory measurements. A
mean for each week was calculated.
Results: In controls, no signiﬁcant change of OBP was observed (baseline: systolic 162.2 ± 11.6 mm Hg vs. 6
months: systolic 162.8 ± 22.9 mm Hg; p N 0.05). Accordingly, HBPM values didn't change (baseline: systolic
161.2±15.1mmHgvs. 6months: systolic 155.8±24.6mmHg, p N 0.05). In RDNpatients a signiﬁcant reduction
of OBP (baseline: systolic 169 ± 12.5 mm Hg vs. 6 months: systolic 150.6 ± 19.2 mm Hg, p b 0.01) and HBPM
(baseline: systolic 156.2 ± 12.9 mm Hg vs. 6 months: systolic 139.7 ± 10.2 mm Hg, p b 0.001) was observed.
Conclusion: In patients with resistant hypertension RDN signiﬁcantly reduced HBPM and OBP already one week
after treatment.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Arterial hypertension is a widespread disease and an important
cardiovascular risk factor [1–2]. [3–5]. Approximately 10% of hypertensive
patients are suffering from resistant arterial hypertension where thera-
peutic targets are not met [6–7]. Therefore resistant arterial hyperten-
sion was deﬁned as a remaining systolic blood pressure (SBP)
≥140 mm Hg despite an antihypertensive treatment with at least
three different drugs including one diuretic [8]. The pathophysiology
is complex and remains, at least in part, unclear. It is known that the
central nervous system is linked and communicates with efferent andswig-Holstein, Campus Lübeck,
n).
. This is an open access article underafferent renal sympathetic nerve ﬁbers that contribute to the develop-
ment and perpetuation of hypertension.
Several interventional approaches to control resistant hypertension
exist. RDN is one of these approaches reducing central sympathetic ac-
tivity [9]. RDN uses radiofrequency energy intercepting afferent and ef-
ferent renal sympathetic nerves. In treated patients, RDN showed a
signiﬁcant reduction of OBP up to 36 months [10–12] as well as
24 hour ambulatory blood pressure measurements (ABPM) up to 24
months [13]. Furthermore, RDN improved central pressures and arterial
stiffness [14–15]. In contrast to previously published promising data [9,
12,16] the Symplicity HTN-3 study [17] –which was the ﬁrst multicen-
ter, randomized trial – didn't show a signiﬁcant reduction of systolic
blood pressure in the 24 hour ABPM compared to a control group treat-
ed with a sham procedure [18].
HBPM is recommended in the management of hypertension since it
e.g. excludes thewhite coat effect andmight help improve hypertension
control [19]. Furthermore out of ofﬁce measurements are strongerthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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However, the already published Symplicity HTN-3 focused only on
OBP and as a secondary endpoint on 24 h-ABPM [17–18]. Taken togeth-
er, it is of great importance to demonstrate the effects of RDN on HBPM.
For this reason,we addressed thequestionwhether RDNwith its known
reduction of peripheral blood pressures and improvement of central
blood pressures [14,30] might also affect HBPM measurements.
Finally since now it remained unclear, when effects after the RDN
procedure might start independently of the OBP or 24 h-ABPM. In the
present study, we therefore determined the beginning of a signiﬁcant
blood pressure reduction by using HBPM besides the effects on ofﬁce
blood pressure.
2. Methods
2.1. Study design and patients
All patients had to fulﬁll the following inclusion criteria [31–32]:
I) age over 18 years; II) peripheral ofﬁce SBP of at least 150 mm Hg at
screening; III) stable treatment with three or more antihypertensive
drugs in maximum tolerable doses of different classes, including di-
uretics. Exclusion criteria were the following: I) an estimated glomeru-
lar ﬁltration rate (GFR) of less than 45 mL/min per 1.73 m2; II)
substantial valvular heart disease, III) pregnancy or planned pregnancy
during the study, IV) history of myocardial infarction, unstable angina,
or cerebral vascular event in the previous six months, or V) signiﬁcant
renal artery stenosis and/or previous renal artery intervention. Addi-
tionally, secondary hypertension including e.g. obstructive sleep apnea
and pseudo-resistancewere extensively ruled out. During the screening
process, each patient was asked to start with a blood pressure logbook
for documentation. The screening visit was two weeks before RDN. 35
patients fulﬁlled the inclusion criteria. 21 patients were treated with
RDNwhile 7 served as controls. The other 7 patients were not included,
because 2 documented HBPM insufﬁciently, 1 didn't appear to the date
of treatment and 4 patients withdrew the written consent. At baseline
visit, blood pressure was measured two days before treatment and doc-
umented as baseline, which was taken for statistical reference of blood
pressure follow-ups. Routine follow-up visits were scheduled as per
protocol at one month (+30 days), three months (+90 days) and six
months (+180 days) after inclusion. The study was approved by the
local ethic committee (AZ 10-211). Before enrollment each patient pro-
vided written informed consent.
2.2. Procedure and follow-up
All ablations were performed by two experienced operators. After
preparing the access a standard endovascular technique was selected
via the right femoral artery. Thereafter the interventionalist probed
the renal artery with the ablation catheter, advanced it into the vessel
and connected the catheter system to a radiofrequency generator
(Medtronic). Applying a maximum of six ablation points per renal ar-
tery using a maximum power of 8W at each single point the procedure
wasperformed by retracting the catheter from the distal to theproximal
part of the artery. The second artery was treated accordingly.
Unfractionated heparin was applied with an activated clotting time of
N250 s. Patients were asked to avoid any change of baseline doses of
anti-hypertensive treatment unless judged medically urgent. This was
described as any relevant changes in blood pressure associated with
signs or even symptoms of severe hypo- or hypertension. As deﬁned
by protocol all patients were asked for follow-up visits at one, three
and six months after the procedure. These follow-up visits included as-
sessment of adverse events and current medication, measurements of
OBP aswell as collecting data of the blood pressure pass. Measurements
of OBP were done according to protocol-speciﬁed guidelines based on
Standard Joint National Committee VII, European Society of Cardiology,
and European Society of Hypertension recommendations [3] and withan automatic oscillometric Omron HEM-705 monitor (Omron
Healthcare, Vernon Hills, IL, USA).
2.3. Endpoints
1. Changes of HBPM from baseline to follow-up. 2. Changes of OBP.
According to the relevant studies in the ﬁeld response was deﬁned as
a reduction of ofﬁce SBP of ≥10 mm Hg [12,32].
2.4. HBPM and blood pressure logbook
All patients used fully automated oscillometric upper arm devices
that were approved by the German Hypertension League (DHL e.V.).
For a detailed documentation patients were asked to measure and re-
port the blood pressure values on a daily basis, i.e. at least twice per
day under the same standard conditions. Patients were trained accord-
ing to the guidelines for blood pressure measurement of the ESH/Ger-
man‚ Hochdruckliga [3,33] and the practice guidelines for home blood
pressure monitoring of the ESH [19]. Measurements were performed
in themorningwithin 1 h afterwaking up, after urinating, beforemorn-
ing antihypertensives, before breakfast and after at least 5min of rest in
a sitting position as well as at bedtime after at least 5min of rest in a sit-
ting position. A patient speciﬁc logbook contained also a detailed
guideline-based manual. The logbooks were copied at each follow-up
visit and immediately entered in our database manually.
2.5. Statistical analysis
The week prior to the ablation served as reference point. “Baseline”
was used as the reference point for the OBP. The HBPM as well as the
OBP were compared by a paired t-test during the follow-up. ANOVA
on ranks (RANOVA) was applied where applicable comparing both
groups. All data are shown as mean ± standard deviation (SD) if not
stated otherwise. A p-value of b0.05 was deﬁned as statistically signiﬁ-
cant. All statistical analyses were performed with SPSS statistical soft-
ware (SPSS 19 Inc., Chicago, USA). Figures as well as tables were
created by SigmaPlot 8.0 (Systat Software Inc., San Jose, USA) and edited
by CorelDraw 11.0 (Corel Inc., Mountain View, USA).
3. Results
3.1. Baseline characteristics
After screening 35 patients fulﬁlled the inclusion criteria and 28 of
them were ﬁnally included (ﬂow-chart Fig. 1). Baseline characteristics
for the RDN (TG) as well as control group (CG) are shown in Table 1.
One patient of the TG refused to complete the follow-up at 6 months.
This patient's data were excluded from statistical analysis for this time
point. Furthermore data of the blood pressure logbook that were miss-
ing at any follow-up were excluded from analysis for this time point.
There were no statistical differences for number of measurements,
number of days or weeks between TG and CG (analyzed weeks of TG
included into statistics: 22.5± 8.8 vs. CG 23.8± 1.9, p ~ 0.754; analyzed
days: TG 157.7 ± 61.8 vs. CG 166.6 ± 13.5, p ~ 0.754; blood pressure
measurements: TG 322.9 ± 158.5 vs. CG 377.8 ± 71.8 single measure-
ments, p ~ 0.462).
3.2. RDN improves systolic and diastolic blood pressures in the OBP
3.2.1. OBP measurements — lowering of systolic as well as diastolic blood
pressure
In the TG, ofﬁce SBP was reduced signiﬁcantly from 169 ±
12.5 mm Hg by approximately 6.3% after one month (p b 0.05) and by
11.9% and 10.9% after three and six months, respectively (p b 0.01,
Table 2, Fig. 2A). Ofﬁce SBP didn't change in the CG. Peripheral diastolic
blood pressure (DBP) showed a trend to improvement at one month
Fig. 1. Flowchart of the study.
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8.7% after three months (p b 0.05) and by 8.7% after six months
(p b 0.05) (Table 2, Fig. 2A).3.3. RDN improves SBP in the HBPM
SBP of the TG improved signiﬁcantly (1 month: 5.8%, p b 0.01; 3
months 7.2%, p b 0.01; 6months 10.6%, p b 0.01) (Fig. 3A). Detailed anal-
ysis showed that the SBP improved already after the ﬁrst week (reduc-
tion by 7.5%, p b 0.01, Fig. 3A). HBPMof the CG didn't change at any time
point signiﬁcantly (Fig. 3A). In addition, TG and CG didn't differ signiﬁ-
cantly at baseline (TG 156.2 ± 12.9mmHg vs. CG 161.2± 15.1mmHg,
p ~ 0.717). During follow-up TG showed signiﬁcantly lower SBP than CG
at one month (p b 0.05) and three months (p b 0.05). At six months,
however, the difference was not signiﬁcant (p ~ 0216).Table 1
Baseline characteristics. Data are expressed as mean ± SD.
Therapy
group
(n = 21)
Control
group
(n = 7) p-Value
Gender [percentage of men] 62% 40% N0.05
Age [years] 67.4 ± 12.3 67.8 ± 10.0 N0.05
Hypercholesterolemia 57% 60% N0.05
Diabetes mellitus 24% 60% N0.05
Adipositas 48% 100% .034
Smoking 29% 60% N0.05
pAVD 24% 20% N0.05
Pulmonary disease 19% 40% N0.05
Height at baseline [m] 1.76 ± .11 1.72 ± .07 N0.05
Weight at baseline [kg] 86.8 ± 19.0 102.9 ± 12.7 N0.05
BMI at baseline [kg/m2] 27.9 ± 4.1 34.8 ± 2.8 .002
Number of drugs 7.3 ± 2.5 7.9 ± 2.4 N0.05
Number of antihypertensive drugs 5.4 ± 1.3 5.1 ± 2.2 N0.05
Number of ablation points of the
left renal artery
4.6 ± 1
Number of ablation points of the
right renal artery
4.6 ± 1.1
Analyzed weeks 22.5 ± 8.8 23.8 ± 1.9 N0.05
Analyzed days 157.7 ± 61.8 166.6 ± 13.5 N0.05
Analyzed measurements 322.9 ± 158.5 377.8 ± 71.8 N0.053.4. RDN improves DBP in the HBPM
DBP of the TG improved signiﬁcantly after one month (reduction by
5.7%, p b 0.01), after three months (reduction by 6.8%, p b 0.001) and
after six months (reduction by 5.1.%, p b 0.001) (Fig. 3B). Comparable
with the effect of RDN on SBP, DBP declined signiﬁcantly after the ﬁrst
week and remained afterwards at this level (p b 0.01). The diastolic
blood pressure of the CG didn't change signiﬁcantly during follow-up
(Fig. 3B). In the ANOVA no differences could be shown between TG
and CG.3.5. No differences occurred between OBP measurements and HBPM
Ofﬁce and HBPM showed no signiﬁcant difference for the mean of
SBP as well as DBP for the TG and CG. SBP of the HBPM of the TG lay
in a range of 92% and 95% and DBP of the HBPM lay between 101%
and 103% compared to the OBP (p N 0.05). The CG achieved systolic
values between 96% and 99% and diastolic values between 95% and
101% in the HBPM compared to the OBP (p N 0.05).4. Discussion
After Symplicity HTN-3 RDN is controversially discussed [17,34].
Joint UK societies' 2014 consensus statement on RDN recommended
no clinical practice but further research [35]. Guidelines are in favor of
HBPM besides 24 h-ABPM compared to OBP measurements in the
management of hypertension. Both methods have proved to overcome
the limitations of OBP measurements [3,36–38]. Consequently, the ESH
and ESC guidelines recommendHBPMandABPMbesides OBPmeasure-
ments [3,20–22]. Although a great number of reported trials, e.g.
Symplicity HTN 1 and 2 trials, as well as various other trials, proved a
signiﬁcant RDN-induced reduction of OBPs [32,39] only a very limited
number of trials are based on out of ofﬁce measurements with ABPM.
The recently published Symplicity HTN-3 showed no signiﬁcant reduc-
tion of ABPM [17–18] in contrast to the data of Lambert [13], who dem-
onstrated a reproducible and signiﬁcant blood pressure reduction in the
ABPM despite a great variation of the OBP. Detailed data of HBPM in the
follow-up after RDNwere up to now lacking. Different studies as well as
meta-analyses had shown that HBPM could predict cardiovascularmor-
bidity and mortality more precisely than OBP measurements.
Table 2
Statistical analysis of the OBP as well as of the HBPM during follow-up. Data are expressed as mean ± SD.
SBP of therapy group SBP of control group p-Value TG vs. CG DBP of therapy group DBP of control group p-Value TG vs. CG
p-Value FU vs. baseline p-Value FU vs. baseline p-value FU vs. Baseline p-Value FU vs.
Baseline
Ofﬁce
Baseline 168.8 ± 3.3 163.3 ± 3.6 92.8 ± 2.5 92.5 ± 4.6 p N 0.05
1 month follow-up 156.5 ± 4.5 p b 0.05 166.5 ± 12.4 p N 0.05 88.5 ± 2.5 p = 0.053 88.4 ± 3.7 p N 0.05 p N 0.05
3 months follow-up 149.0 ± 4.6 p b 0.01 164.8 ± 9.8 p N 0.05 84.7 ± 3.1 p b 0.05 91.6 ± 4.4 p N 0.05 p N 0.05
6 months follow-up 150.6 ± 4.2 p b 0.01 159.4 ± 6.0 p N 0.05 84.9 ± 2.4 p b 0.05 90.9 ± 4.8 p N 0.05 p N 0.05
Out of ofﬁce/HBPM
One week before RDN 156.2 ± 3.0 161.2 ± 6.8 p N 0.05 p N 0.05 92.1 ± 2.4 p b 0.01 90.5 ± 7.0 p N 0.05
Week of RDN 144.5 ± 4.0 86.7 ± 2.7
One week after RDN 144.0 ± 3.6 p b 0.01 85.8 ± 2.5 p b 0.01
Two weeks after RDN 144.4 ± 3.2 p b 0.01 85.5 ± 2.2 p b 0.01
Four weeks after RDN 146.2 ± 3.3 p b 0.01 167.1 ± 7.1 p N 0.05 p b 0.05 86.8 ± 2.6 p b 0.01 92.9 ± 7.1 p N 0.05
13 weeks after RDN 141.5 ± 3.6 p b 0.01 168.3 ± 10.0 p N 0.05 p b 0.05 83.8 ± 2.6 p b 0.01 93.7 ± 9.2 p N 0.05
26 weeks after RDN 139.7 ± 3.2 p b 0.01 155.8 ± 11.0 p N 0.05 p N 0.05 82.1 ± 2.9 p b 0.01 90.0 ± 6.9 p N 0.05
Fig. 2. RDN improves OBP (Omron™ device). Effects of RDN on ofﬁce systolic blood
pressure (SBP, A) and on ofﬁce diastolic blood pressure (DBP, B). Measurementswere per-
formed with an Omron™ device with the patient in sitting position. Asterisks indicate
signiﬁcant reduction of blood pressure values as compared to baseline. Data are expressed
as mean ± sem.
Fig. 3. RDN improves HBPM. Effects of RDN on out of ofﬁce systolic blood pressure (SBP,
A) and on out of ofﬁce diastolic blood pressure (DBP, B). Measurements were performed
with patients' device in a sitting position. Asterisks indicate signiﬁcant reduction of
blood pressure values as compared to baseline. Data are expressed as mean ± sem.
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(a) RDN improves peripheral OBP and (b) out of ofﬁce measurements
like 24-h ABPM [40]. In addition we describe for the ﬁrst time that 1.
RDN has favorable effects on HBPM also compared to a CG and 2. signif-
icant blood pressure effects of RDN commence already one week after
index ablation. During follow-up it seemed that there was a trend to
an increase of the systolic blood pressure after six months. These ﬁnd-
ings are in line with the latest publication of the working group of
Booth with the postulation of a reinnervation which led to an increase
of the systolic blood pressure over the time [41]. Therefore a long-
term analysis of HBPM based on blood pressure logbooks is urgently
needed.
4.1. Limitations
Limitations of our study were (a) the relatively small number of pa-
tients, (b) the short follow-up period of 6 months and (c) a missing
shame ablation. Especially the missing shame ablation might be of im-
portance, since some criticismmay occur that the described blood pres-
sure effects are based on a potential better compliance of included
patients. The data of the control group showed no decline in systolic
blood pressure and even these patients had higher systolic blood pres-
sures during follow-up. Further analysis with a longer follow-up time
as well as a shame ablation is needed in future studies to investigate
the effects on blood pressure after RDN. Furthermore a strictmedication
surveillance should be implemented in these studies to ensure the pa-
tients' compliance.
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